Wall Street analysts expect Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) to announce earnings of ($0.82) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Eiger Biopharmaceuticals’ earnings. The lowest EPS estimate is ($1.13) and the highest is ($0.60). Eiger Biopharmaceuticals reported earnings per share of ($1.10) during the same quarter last year, which would suggest a positive year-over-year growth rate of 25.5%. The company is expected to issue its next earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Eiger Biopharmaceuticals will report full-year earnings of ($3.19) per share for the current financial year, with EPS estimates ranging from ($4.22) to ($2.71). For the next financial year, analysts expect that the company will post earnings of ($3.24) per share, with EPS estimates ranging from ($3.82) to ($2.60). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings results on Friday, August 10th. The biotechnology company reported ($0.82) earnings per share for the quarter, meeting the consensus estimate of ($0.82).

Several research firms recently weighed in on EIGR. ValuEngine cut shares of Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, September 17th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $24.00 price target on shares of Eiger Biopharmaceuticals in a report on Wednesday, May 30th. Zacks Investment Research cut shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 31st. Oppenheimer set a $26.00 target price on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 14th. Finally, Wedbush set a $53.00 target price on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a report on Monday, September 10th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. Eiger Biopharmaceuticals currently has a consensus rating of “Buy” and an average price target of $30.75.

NASDAQ:EIGR traded up $0.15 during trading hours on Tuesday, hitting $12.00. The company had a trading volume of 11,900 shares, compared to its average volume of 139,391. The stock has a market cap of $165.23 million, a P/E ratio of -2.47 and a beta of 1.79. Eiger Biopharmaceuticals has a 52 week low of $7.46 and a 52 week high of $18.00. The company has a quick ratio of 8.49, a current ratio of 8.49 and a debt-to-equity ratio of 0.35.

Hedge funds have recently made changes to their positions in the company. DRW Securities LLC bought a new stake in shares of Eiger Biopharmaceuticals during the 1st quarter valued at $158,000. Bank of New York Mellon Corp boosted its holdings in shares of Eiger Biopharmaceuticals by 36.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 20,412 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 5,492 shares in the last quarter. Algert Global LLC bought a new stake in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at $277,000. Ardsley Advisory Partners bought a new stake in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at $305,000. Finally, Northern Trust Corp boosted its holdings in shares of Eiger Biopharmaceuticals by 169.7% during the 1st quarter. Northern Trust Corp now owns 29,376 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 18,483 shares in the last quarter. Hedge funds and other institutional investors own 69.28% of the company’s stock.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Further Reading: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Eiger Biopharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.